227 related articles for article (PubMed ID: 25845317)
21. Molecular mechanisms of melanoma.
Pickert A
Cutis; 2012 Mar; 89(3):E1-4. PubMed ID: 23961517
[No Abstract] [Full Text] [Related]
22. Recognition, Staging, and Management of Melanoma.
Rashid S; Tsao H
Med Clin North Am; 2021 Jul; 105(4):643-661. PubMed ID: 34059243
[TBL] [Abstract][Full Text] [Related]
23. [New treatments for metastatic melanoma: a first hope].
Robert C; Mateus C
Rev Prat; 2011 Nov; 61(9 Suppl):S1-2. PubMed ID: 22338196
[No Abstract] [Full Text] [Related]
24. Emerging targeted therapies for melanoma.
Johnson DB; Pollack MH; Sosman JA
Expert Opin Emerg Drugs; 2016 Jun; 21(2):195-207. PubMed ID: 27148822
[TBL] [Abstract][Full Text] [Related]
25. [Future targeting of the RAS/RAF/MEK/ERK signaling pathway in oncology: the example of melanoma].
Favre G
Bull Acad Natl Med; 2014 Feb; 198(2):321-36; discussion 337-8. PubMed ID: 26263707
[TBL] [Abstract][Full Text] [Related]
26. Towards personalized therapy for patients with malignant melanoma: molecular insights into the biology of BRAF mutations.
Bradish JR; Montironi R; Lopez-Beltran A; Post KM; MacLennan GT; Cheng L
Future Oncol; 2013 Feb; 9(2):245-53. PubMed ID: 23414474
[TBL] [Abstract][Full Text] [Related]
27. [BRAF mutation: a novel approach in targeted melanoma therapy].
Arenbergerová M; Puzanov I
Klin Onkol; 2012; 25(5):323-8. PubMed ID: 23102192
[TBL] [Abstract][Full Text] [Related]
28. Immunotherapy for melanoma.
Cuevas LM; Daud AI
Semin Cutan Med Surg; 2018 Jun; 37(2):127-131. PubMed ID: 30040090
[TBL] [Abstract][Full Text] [Related]
29. Oligoprogression After Immunotherapy and Targeted Therapy in Metastatic Melanoma.
Sobrevilla-Moreno N; Rivera-Sánchez D; García-Ortega D; López-Macías D; Garcilazo-Reyes A; Álvarez-Avitia M
Oncology (Williston Park); 2021 Sep; 35(9):562-566. PubMed ID: 34529396
[No Abstract] [Full Text] [Related]
30. [Melanoma and search for therapeutic targets].
de la Fouchardière A
Ann Pathol; 2011 Nov; 31(5 Suppl):S123-4. PubMed ID: 22054449
[No Abstract] [Full Text] [Related]
31. Active surrender.
Collisson EA
Pigment Cell Melanoma Res; 2012 May; 25(3):292-3. PubMed ID: 22629566
[No Abstract] [Full Text] [Related]
32. [Cellular and molecular mechanisms of carcinogenic side effects and resistance to BRAF inhibitors in metastatic melanoma with BRAFV600 mutation: state of the knowledge].
Capovilla M
Ann Pathol; 2013 Dec; 33(6):375-85. PubMed ID: 24331719
[TBL] [Abstract][Full Text] [Related]
33. Assessment of clinical parameters associated with mutational status in metastatic malignant melanoma: a single-centre investigation of 141 patients.
Schlaak M; Bajah A; Podewski T; Kreuzberg N; von Bartenwerffer W; Wardelmann E; Merkelbach-Bruse S; Büttner R; Mauch C; Kurschat P
Br J Dermatol; 2013 Apr; 168(4):708-16. PubMed ID: 23528057
[TBL] [Abstract][Full Text] [Related]
34. Targeted therapy resistance mechanisms and therapeutic implications in melanoma.
Chen G; Davies MA
Hematol Oncol Clin North Am; 2014 Jun; 28(3):523-36. PubMed ID: 24880945
[TBL] [Abstract][Full Text] [Related]
35. BRAF mutation status is an independent prognostic factor for resected stage IIIB and IIIC melanoma: implications for melanoma staging and adjuvant therapy.
Barbour AP; Tang YH; Armour N; Dutton-Regester K; Krause L; Loffler KA; Lambie D; Burmeister B; Thomas J; Smithers BM; Hayward NK
Eur J Cancer; 2014 Oct; 50(15):2668-76. PubMed ID: 25070294
[TBL] [Abstract][Full Text] [Related]
36. Treatment implications of the emerging molecular classification system for melanoma.
Romano E; Schwartz GK; Chapman PB; Wolchock JD; Carvajal RD
Lancet Oncol; 2011 Sep; 12(9):913-22. PubMed ID: 21349766
[TBL] [Abstract][Full Text] [Related]
37. Association between the germline MC1R variants and somatic BRAF/NRAS mutations in melanoma tumors.
Scherer D; Rachakonda PS; Angelini S; Mehnert F; Sucker A; Egberts F; Hauschild A; Hemminki K; Schadendorf D; Kumar R
J Invest Dermatol; 2010 Dec; 130(12):2844-8. PubMed ID: 20720566
[No Abstract] [Full Text] [Related]
38. [Gene abnormalities in melanoma and signal transduction antagonists].
Takada M
Gan To Kagaku Ryoho; 2013 Apr; 40(4):453-7. PubMed ID: 23894754
[No Abstract] [Full Text] [Related]
39. Research progress in advanced melanoma.
Luo C; Shen J
Cancer Lett; 2017 Jul; 397():120-126. PubMed ID: 28385603
[TBL] [Abstract][Full Text] [Related]
40. A new era in the treatment of melanoma: from biology to clinical practice.
Márquez-Rodas I; Martín Algarra S; Avilés Izquierdo JA; Custodio Cabello S; Martín M
Clin Transl Oncol; 2011 Nov; 13(11):787-92. PubMed ID: 22082642
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
